Twin Impex

Twin Impex Private Limited, established on August 14, 1997, is a private limited company based in Navi Mumbai, Maharashtra, India. The company was incorporated under the Corporate Identification Number (CIN) U51900MH1997PTC110097. Its registered office is located at E-16, RH-IV, Sector 6, Vashi, Navi Mumbai 400 703, Maharashtra, India.

As of the latest available records, Twin Impex is classified as a non-government company and is unlisted. The authorized capital is ₹100,000, with a paid-up capital of ₹0. The company has been marked as "struck off," indicating that it is no longer active in business operations.

There is no publicly available information regarding the manufacturing facilities of Twin Impex Private Limited. The company's current status as "struck off" suggests that it may not have active manufacturing operations.

The latest available records do not provide specific details about the key leadership of Twin Impex Private Limited. Given the company's "struck off" status, it is likely that the leadership team is no longer active or has been dissolved.

Twin Impex Private Limited has engaged in export activities, with a total export value of $141,000 USD across 24 shipments. The company has exported products to various markets, including Guinea, Senegal, and Angola. The primary products exported are Acetylsalicylic and Niacin, which fall under the therapeutic categories of Combination Drugs and Lipid & Metabolism, respectively. However, the company's current "struck off" status may affect its ability to maintain regulatory approvals and market access in these regions.

Twin Impex Private Limited has engaged in export activities to emerging markets such as Guinea, Senegal, and Angola. The company's export data indicates shipments to these countries, suggesting a presence in these regions. However, the company's current "struck off" status may impact its ability to continue operations in these markets.

Twin Impex Private Limited's export activities have been concentrated in specific markets, including Guinea, Senegal, and Angola. This focus indicates a strategic approach targeting emerging markets. However, the company's current "struck off" status suggests a lack of diversification in its geographic strategy, potentially exposing it to risks associated with over-reliance on a limited number of markets.

There is no publicly available information regarding Twin Impex Private Limited's registration with the U.S. Food and Drug Administration (FDA), approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history. Given the company's "struck off" status, it is unlikely that the company holds active FDA approvals or registrations.

There is no publicly available information indicating that Twin Impex Private Limited holds World Health Organization (WHO) prequalification or European Union Good Manufacturing Practice (EU GMP) certificates. The company's current "struck off" status suggests that it may not possess these certifications.

There is no publicly available information regarding Twin Impex Private Limited's manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), approvals from state drug controllers, or export No Objection Certificates (NOCs). The company's "struck off" status indicates that it may not hold active regulatory approvals or licenses.

There is no publicly available information regarding any Form 483 observations, warning letters, or import alerts issued to Twin Impex Private Limited. The company's current "struck off" status suggests that it is not subject to recent regulatory actions.

Given the company's "struck off" status, Twin Impex Private Limited is no longer an active competitor in the pharmaceutical export market. Therefore, a competitive analysis is not applicable.

As Twin Impex Private Limited is currently "struck off" and no longer active, it does not possess any key differentiators or competitive advantages in the market.

Twin Impex Private Limited's strategic direction, focusing on exporting finished pharmaceutical formulations such as Acetylsalicylic and Niacin, indicates a specialization in specific therapeutic categories. However, the company's current "struck off" status suggests that it is no longer pursuing this strategic direction.

As Twin Impex Private Limited is currently "struck off" and no longer active, it is not a viable supplier. Therefore, an assessment of its track record, export volume, consistency, and reliability is not applicable.

Given the company's "struck off" status, Twin Impex Private Limited is not an active exporter, and therefore, there are no certifications to verify.

As Twin Impex Private Limited is currently "struck off" and no longer active, there are no actionable verification steps, red flags, or recommended pre-order checks applicable to this company.